JPWO2022125566A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022125566A5 JPWO2022125566A5 JP2023534636A JP2023534636A JPWO2022125566A5 JP WO2022125566 A5 JPWO2022125566 A5 JP WO2022125566A5 JP 2023534636 A JP2023534636 A JP 2023534636A JP 2023534636 A JP2023534636 A JP 2023534636A JP WO2022125566 A5 JPWO2022125566 A5 JP WO2022125566A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- polypeptide
- cdr1
- cdr2
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 35
- 229920001184 polypeptide Polymers 0.000 claims 34
- 102000004196 processed proteins & peptides Human genes 0.000 claims 34
- 125000003275 alpha amino acid group Chemical group 0.000 claims 10
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 8
- 125000000539 amino acid group Chemical group 0.000 claims 6
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 4
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 3
- 239000000427 antigen Substances 0.000 claims 3
- 102000036639 antigens Human genes 0.000 claims 3
- 108091007433 antigens Proteins 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims 2
- 238000012986 modification Methods 0.000 claims 2
- 230000004048 modification Effects 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 108091005804 Peptidases Proteins 0.000 claims 1
- 239000004365 Protease Substances 0.000 claims 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000758 substrate Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063122818P | 2020-12-08 | 2020-12-08 | |
| US63/122,818 | 2020-12-08 | ||
| PCT/US2021/062238 WO2022125566A1 (en) | 2020-12-08 | 2021-12-07 | Half-life extending compositions and methods |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023552462A JP2023552462A (ja) | 2023-12-15 |
| JP2023552462A5 JP2023552462A5 (https=) | 2024-12-12 |
| JPWO2022125566A5 true JPWO2022125566A5 (https=) | 2024-12-12 |
Family
ID=81973740
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023534636A Pending JP2023552462A (ja) | 2020-12-08 | 2021-12-07 | 半減期延長組成物および方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240034814A1 (https=) |
| EP (1) | EP4259178A4 (https=) |
| JP (1) | JP2023552462A (https=) |
| KR (1) | KR20230156897A (https=) |
| CN (1) | CN117042788A (https=) |
| AU (1) | AU2021397734A1 (https=) |
| CA (1) | CA3201560A1 (https=) |
| MX (1) | MX2023006732A (https=) |
| WO (1) | WO2022125566A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2021287998B2 (en) | 2020-06-11 | 2026-03-12 | Benaroya Research Institute At Virginia Mason | Methods and compositions for preventing type 1 diabetes |
| AU2021396172A1 (en) | 2020-12-09 | 2023-07-06 | Janux Therapeutics, Inc. | Compositions and methods related to tumor activated antibodies targeting psma and effector cell antigens |
| US12565529B2 (en) | 2021-05-24 | 2026-03-03 | Provention Bio, Inc. | Methods for treating type 1 diabetes |
| GB2641580A (en) | 2024-06-07 | 2025-12-10 | T Therapeutics Ltd | Tumour-transforming multispecific proteins |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1355919E (pt) * | 2000-12-12 | 2011-03-02 | Medimmune Llc | Moléculas com semivida longa, composições que as contêm e suas utilizações |
| WO2004041867A2 (en) * | 2002-11-08 | 2004-05-21 | Ablynx N.V. | Camelidae antibodies against imminoglobulin e and use thereof for the treatment of allergic disorders |
| SG173488A1 (en) * | 2009-02-19 | 2011-09-29 | Glaxo Group Ltd | Improved anti-serum albumin binding variants |
| CN111433224B (zh) * | 2017-11-17 | 2024-03-19 | 南京传奇生物科技有限公司 | 抗pd-l1的单结构域抗体及其变体 |
| WO2019204925A1 (en) * | 2018-04-24 | 2019-10-31 | National Research Council Of Canada | Serum albumin binding antibodies for tuneable half-life extension of biologics |
| CN113508134B (zh) * | 2019-02-22 | 2024-12-03 | 安维达生物科技公司 | 白蛋白结合抗体及其用途 |
-
2021
- 2021-12-07 CN CN202180091880.6A patent/CN117042788A/zh active Pending
- 2021-12-07 US US18/256,276 patent/US20240034814A1/en active Pending
- 2021-12-07 KR KR1020237022999A patent/KR20230156897A/ko active Pending
- 2021-12-07 EP EP21904262.9A patent/EP4259178A4/en active Pending
- 2021-12-07 AU AU2021397734A patent/AU2021397734A1/en active Pending
- 2021-12-07 MX MX2023006732A patent/MX2023006732A/es unknown
- 2021-12-07 JP JP2023534636A patent/JP2023552462A/ja active Pending
- 2021-12-07 WO PCT/US2021/062238 patent/WO2022125566A1/en not_active Ceased
- 2021-12-07 CA CA3201560A patent/CA3201560A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021020905A5 (https=) | ||
| JP2020114210A5 (https=) | ||
| JP2021159081A5 (https=) | ||
| CN115057936A (zh) | 异源二聚体多特异性抗体形式 | |
| JP2020505919A5 (https=) | ||
| JP2023123649A5 (https=) | ||
| JP2024113040A5 (https=) | ||
| JP2026004299A5 (https=) | ||
| ME02653B (me) | Genski proizvodi koji su diferencijalno izraženi u tumorima i njihova primjena | |
| JPWO2021116182A5 (https=) | ||
| JP2025124718A5 (https=) | ||
| AR129202A1 (es) | Anticuerpos activados por tumores que se dirigen a trop2 y usos de estos | |
| JPWO2020247871A5 (https=) | ||
| JPWO2020011976A5 (https=) | ||
| JPWO2022094299A5 (https=) | ||
| JPWO2022035866A5 (https=) | ||
| JPWO2022125566A5 (https=) | ||
| IL322564A (en) | Prostate-specific membrane antigen (PSMA)-targeting compositions and methods for their preparation and use | |
| JPWO2021007260A5 (https=) | ||
| AU2019232759A1 (en) | Anti-TIP-1 antibodies and uses thereof | |
| WO2024061224A1 (zh) | 抗her2抗体及其用途 | |
| JPWO2022129560A5 (https=) | ||
| JPWO2023068377A5 (https=) | ||
| JPWO2022190018A5 (https=) | ||
| WO2021256524A1 (ja) | 免疫原性低減型低分子抗体とその製造法 |